

Anti-CTLA-4/CD152 Antibody (Ipilimumab)

Introduction

Ipilimumab is a fully human monoclonal IgG1 κ antibody that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab is being studied in unresectable or metastatic melanoma (MM).

Product parameters

Alternative Names	Yervoy, MDX-010, MDX101
Target Accession	P16410
Target	CTLA-4 / CD152
CAS number	477202-00-9
Molecular Weight	145.38 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2270 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

